ReviewDiabetologia2010
The clinical significance of hyperfiltration in diabetes.
Review in Diabetologia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02911792 (Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration), which is not on this map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Who cites it
76 citing papers in PubMed, 196 citations in OpenAlex.
- Glomerular hyperfiltration and renal disease progression in type 2 diabetes.Diabetes care · 2012 · on this mapTrial
- Impact of Empagliflozin on Glomerular Hyperfiltration and Albuminuria in Youth with Type 2 Diabetes: Post Hoc Analysis of DINAMO.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Severe obesity associates with maladaptive glomerular haemodynamics clustered with insulin resistance and endothelial dysfunction.Clinical kidney journal · 2025Article
- Definition of hyperfiltration taking into account age-related decline in renal function in kidney donor candidates with obesity and glucose tolerance disorder.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Risk factors for rapid kidney function decline in diabetes patients.Renal failure · 2024Review
- Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Pathomechanisms of Diabetic Kidney Disease.Journal of clinical medicine · 2023Review
- The association between renal hyperfiltration and mortality is not mediated by diabetes mellitus.International urology and nephrology · 2023Article
- Glomerular hyperfiltration: part 2-clinical significance in children.Pediatric nephrology (Berlin, Germany) · 2023Review
- Expression of growth arrest specific 1 (Gas1) in the distal tubules and collecting ducts in normal kidney and in the early stages of diabetic nephropathy.Journal of molecular histology · 2022Article
- Methods for Assessment of the Glomerular Filtration Rate in Laboratory Animals.Kidney diseases (Basel, Switzerland) · 2022Review
- Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.Diabetes & metabolism journal · 2022Review
- Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis.Frontiers in pharmacology · 2022Article
- Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease.Frontiers in endocrinology · 2022Review
- L-NAME Administration Enhances Diabetic Kidney Disease Development in an STZ/NAD Rat Model.International journal of molecular sciences · 2021Article
- The association of glucose metabolism and kidney function in middle-aged adults.Clinical kidney journal · 2021Article
- Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.Clinical pharmacology in drug development · 2021Article
- Independent and interactive effects of kidney stone formation and conventional risk factors for chronic kidney disease: a follow-up study of Japanese men.International urology and nephrology · 2021Article
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.Nature reviews. Nephrology · 2021Review
- Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.Nephrology (Carlton, Vic.) · 2021Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glomerular filtration rate is commonly elevated in early diabetes and patients with this symptom are arbitrarily considered to have hyperfiltration. The prevalence of hyperfiltration in type 1 diabetes varies from less than 25% to more than 75%. The corresponding figures in type 2 diabetes are significantly lower, ranging between 0% and more than 40%. Several factors, methodological and biological, may contribute to the wide variation in estimates of hyperfiltration prevalence. Methodological differences in measurement and evaluation of GFR apply in particular to the handling of plasma disappearance curves of filtration markers. Biological factors that may influence GFR in the hyperfiltration range include glycaemic control, diabetes duration, BMI, sex, pubertal status in type 1 diabetes and age in type 2 diabetes. Hyperglycaemia may influence GFR and albuminuria, and may therefore confound the evaluation of hyperfiltration as an independent risk factor for diabetic nephropathy. Adequate assessment of the relationship between glycaemic control, GFR and AER therefore requires serial measurements of all three variables followed by multivariate analysis. A recent meta-analysis of ten type 1 diabetes studies concluded that the presence of hyperfiltration at baseline more than doubled the risk of developing micro- or macroalbuminuria at follow-up. However, not all studies allowed for confounding factors or regression dilution bias. Future studies will therefore need to address the independent role of hyperfiltration, not only in the evolution of albuminuria, but also in the subsequent decline of GFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.